Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and postoperative neurocognitive recovery in gastrointestinal tumor surgery
ChiCTR2600116225Phase 4Recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in post-operative cognitive decline (POCD), postoperative delirium (POD) and postoperative pain (2 arms), sponsored by The First Hospital of Lanzhou University. Primary endpoint: Incidence of delayed neurocognitive recovery (dNCR) on postoperative day 1. Started Dec 2025; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
post-operative cognitive decline (POCD)postoperative delirium (POD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2600116225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116225.